



TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(e))			Docket No. DI-4641 CONT	
In Re Application Of: Martis et al.				
Serial No. 09/955,248	Filing Date September 17, 2001	Examiner R. Keys	Group Art Unit 1621	
Title: BIOCHEMICALLY BALANCED PERITONEAL DIALYSIS SOLUTIONS				
Address to: Assistant Commissioner for Patents Washington, D.C. 20231				
37 CFR 1.97(b)				
1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.				
37 CFR 1.97(c)				
2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:				
<div style="margin-left: 40px;"> <input type="checkbox"/> the statement specified in 37 CFR 1.97(e); </div>				
OR				
<div style="margin-left: 40px;"> <input type="checkbox"/> the fee set forth in 37 CFR 1.17(p). </div>				



#7
 5/15/02
 J. M. Chen

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(e))			Docket No. DI-4641 CONT
In Re Application: Martis et al.			
Serial No. 09/955,248	Filing Date September 17, 2001	Examiner R. Keys	Group Art Unit 1621
<p style="text-align: center;">BIOCHEMICALLY BALANCED PERITONEAL DIALYSIS SOLUTIONS</p>			
<p style="text-align: center;">Payment of Fee</p> <p style="text-align: center;">(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))</p> <p> <input type="checkbox"/> A check in the amount of _____ is attached. <input checked="" type="checkbox"/> The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 02-1818 as described below. A duplicate copy of this sheet is enclosed. </p> <p> <input type="checkbox"/> Charge the amount of _____ <input checked="" type="checkbox"/> Credit any overpayment. <input checked="" type="checkbox"/> Charge any additional fee required. </p> <div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p style="text-align: center;">Certificate of Transmission by Facsimile*</p> <div style="border: 1px solid black; padding: 5px; margin-bottom: 5px;"> I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F </div> <div style="border: 1px solid black; padding: 5px; margin-bottom: 5px;"> <div style="border-bottom: 1px solid black; width: 100%;"></div> <div style="text-align: center;">(Date)</div> </div> <div style="border: 1px solid black; padding: 5px; margin-bottom: 5px;"> <div style="border-bottom: 1px solid black; width: 100%;"></div> <div style="text-align: center;">Signature</div> </div> <div style="border: 1px solid black; padding: 5px;"> <div style="border-bottom: 1px solid black; width: 100%;"></div> <div style="text-align: center;">Typed or Printed Name of Person Signing Certificate</div> </div> </div> <div style="width: 45%;"> <p style="text-align: center;">Certificate of Mailing by First Class Mail</p> <div style="border: 1px solid black; padding: 5px; margin-bottom: 5px;"> I certify that this document and fee is being deposited 4/30/2002 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231. </div> <div style="border: 1px solid black; padding: 5px; margin-bottom: 5px;"> <div style="border-bottom: 1px solid black; width: 100%;"></div> <div style="text-align: center;">Signature of Person Mailing Correspondence</div> </div> <div style="border: 1px solid black; padding: 5px; margin-bottom: 5px;"> <div style="border-bottom: 1px solid black; width: 100%;"></div> <div style="text-align: center;">Robert Buccieri</div> </div> <div style="border: 1px solid black; padding: 5px;"> <div style="border-bottom: 1px solid black; width: 100%;"></div> <div style="text-align: center;">Typed or Printed Name of Person Mailing Certificate</div> </div> </div> </div> <p style="margin-top: 10px;"> *This certificate may only be used if paying by deposit account. </p> <div style="display: flex; justify-content: space-between; align-items: flex-end; margin-top: 20px;"> <div style="width: 45%;"> <div style="border-bottom: 1px solid black; width: 100%;"></div> <div style="text-align: center;">Signature</div> <p>Robert M. Barrett (30,142) ATTORNEYS FOR APPLICANT Bell, Boyd & Lloyd LLC P.O. Box 1135 Chicago, Illinois 60690-1135</p> </div> <div style="width: 45%;"> <p>Dated: April 30, 2002</p> </div> </div> <p style="margin-top: 20px;">CC:</p>			



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Martis et al.
Appl. No.: 09/955,248
Filed: September 17, 2001
Title: BIOCHEMICALLY BALANCED PERITONEAL DIALYSIS SOLUTIONS
Art Unit: 1621
Examiner: R. Keys
Docket No.: DI-4641 CONT

Commissioner for Patents
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 37 C.F.R. 1.97, and 37 C.F.R. 1.98, Applicants request that a citation and examination of the references cited below, and on the attached PTO-1449 form, copies of which can be found in the parent, application no. 08/421,020, filed on April 12, 1995, be made during the course of examination of the above-identified application for United States patent.

U.S. PATENT DOCUMENTS

<u>Document No.</u>	<u>Date</u>	<u>Inventor</u>
4,396,383	8/2/1983	Hart
4,465,488	8/14/1984	Richmond et al.
4,584,176	4/22/1986	Oliver et al.
4,630,727	12/3/1986	Feriani et al.
4,663,166	5/5/1987	Veech
4,756,838	7/12/1988	Veltman
4,863,714	9/5/1989	Sovak et al.
4,879,280	11/7/1989	Seyffart et al.
4,959,175	9/25/1990	Yatzidis
5,039,609	8/13/1991	Klein
5,141,492	8/25/1992	Dadson et al.
5,383,324	1/24/1995	Segers et al.
5,423,421	6/13/1995	Inoue et al.
5,431,496	7/11/1995	Balteau et al.
5,462,526	10/31/1995	Barney et al.

5,509,898	4/23/1996	Isono et al.
5,536,469	7/16/1996	Jonsson et al.
5,560,403	10/1/1996	Balteau et al.
5,610,170	3/11/1997	Inoue et al.
5,706,937	1/13/1998	Futagawa et al.
5,853,388	12/29/1998	Semel
5,871,477	2/16/1999	Isono et al.
5,945,129	8/31/1999	Knerr et al.

FOREIGN PATENT DOCUMENTS

<u>Document No.</u>	<u>Date</u>	<u>Country</u>
56164113	17/12/1981	Japan
0 083 360	10/7/1981	Europe
0 165 933 B1	2/1/1986	Europe
WO 86/03407	19/6/1986	PCT
WO 87/03809	2/7/1987	PCT
0 249 667 B1	23/12/1987	Europe
0 277 868	8/10/1988	Europe
0 278 100	17/6/1988	Europe
0 209 607	20/12/1989	Europe
0 399 549	28/11/1990	Europe (Including Translation)
2304026	17/12/1990	Japan
0 439 061 B1	31/7/1991	Europe
3195561	27/8/1991	Japan
WO 91/18610	12/12/1991	PCT
5105633	27/4/1993	Japan
6105905	19/4/1994	Japan
0 613 688 A1	7/9/1994	Europe
0 647 145 B1	12/4/1995	Europe
WO 95/19778	27/7/1995	PCT
7252137	3/10/1995	Japan
WO 96/01118	18/1/1996	PCT
8131542	28/5/1996	Japan

8164199	25/6/1996	Japan
WO 97/05851	20/2/1997	PCT
9087182	31/3/1997	Japan
9110703	28/4/1997	Japan
0 776 649 A2	4/6/1997	Europe
9301875	25/11/1997	Japan
2 735 099	13/3/1998	France
98/10733	19/3/1998	PCT
10201821	4/8/1998	Japan
11004872	12/1/1999	Japan
99/01144	14/1/1999	PCT
11-9659	19/1/1999	Japan (Laid-Open Publication Including Translation)
11019178	26/1/1999	Japan
99/09953	4/3/1999	PCT (Abstract Only)
19748290	6/5/1999	Germany
99/22746	14/5/1999	PCT
99/27885	10/6/1999	PCT
0 935 967	18/8/1999	Europe (Including Translation)
0 845 970	26/1/2000	Europe

OTHER DOCUMENTS

American Society for Artificial Internal Organs, 1994 Abstracts.

Boen ST, *A Clinical Study of Factors Governing its Effectiveness*, Peritoneal Dialysis, p. 76, Van Gorcum & Co., Assen, The Netherlands (1959).

Faller et al., "Loss of Ultrafiltration in Continuous Ambulatory Peritoneal Dialysis: A Role for Acetate", Peritoneal Dialysis Bulletin, January-March 1984, pp. 10-13.

Feriani et al., *Bicarbonate Solutions for Peritoneal Dialysis: A Reality*, Int J Artif Organs 8:57-58 (1985).

Ing et al., *Preparation of Bicarbonate-Containing Dialysate for Peritoneal Dialysis*, Int J Artif Organs, Vol. 6, No. 4, pp. 217-218 (1983).

Ing et al., *Lactate-Containing Peritoneal Dialysis Solutions*, Int J Artif Organs, Vol. 16, No. 10, pp. 688-693 (1993).

The Merck Index, 12th Ed., Merck Research Laboratories, Whitehouse Station, NJ, p. 1472 (1996).

Murphey et al., *Use of an Artificial Kidney*, J. Lab. Clin. Med., Volume 40, pp. 436-444 (1952).

Odel HM et al., *Peritoneal Lavage as an Effective Means of Extrarenal Excretion. A Clinical Appraisal*, American Journal of Medicine, Vol. 9, 63-88 (1950).

Schambye et al., *The Cytotoxicity of Continuous Ambulatory Peritoneal Dialysis Solutions with Different Bicarbonate/Lactate Ratios*, Peritoneal Dialysis International, Vol. 13, Suppl. 2; Oct. 1-4/92, pp. S116-S118.

Simonsen et al., *Less Infusion Pain and Elevated Level of Cancer Antigen 125 by the Use of a New and More Biocompatible PD Fluid*, Advances in Peritoneal Dialysis, Vol. 12, pp. 156-160 (1996).


T.S. Ing. et al., *Bicarbonate-Buffered Peritoneal Dialysis*, The International Journal of Artificial Organs, Volume 8, No. 3, p. 121-124 (1985).

Applicants look forward to early and favorable consideration of this matter.

Respectfully submitted,

BELL, BOYD & LLOYD LLC

BY



Robert M. Barrett
Reg. No. 30,142
P.O. Box 1135
Chicago, Illinois 60690-1135
Phone: (312) 807-4204